Greenland Mines (NASDAQ: GRML) announced that IP Australia has granted Australian Patent No. 2023252508 covering gene therapy technology exclusively licensed by the company’s Biotech Division for the treatment of neuromuscular diseases through expression of the human Klotho protein. The patent strengthens the intellectual property supporting Greenland Mines’ Klotho-based therapeutic platform and includes claims covering gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems.
The company said the patent further supports development of its KLTO-202 program targeting amyotrophic lateral sclerosis (“ALS”) and other neuromuscular disorders. ALS, also known as Lou Gehrig’s disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. The KLTO-202 program aims to deliver the Klotho gene to patients, potentially slowing disease progression.
This patent grant is a significant milestone for Greenland Mines as it expands the geographic scope of its intellectual property protection. The company already holds patents in other jurisdictions, and the Australian patent provides additional coverage in a key market for clinical development and future commercialization. The patent includes claims related to gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems, covering multiple aspects of the technology.
Greenland Mines is a Nasdaq-listed company with two operating divisions: Mining and Biotech. The Mining division focuses on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of a previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland. The Biotech division includes Klotho’s KLTO-202 primary indication for ALS.
The company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
For more information, the full press release is available at https://nnw.fm/PVbbH. The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML.
Forward-looking statements in this article involve risks and uncertainties, as defined in the Private Securities Litigation Reform Act of 1995, and actual results may differ materially. These statements are based on information available as of the date hereof, and the company undertakes no duty to update them unless required by law.
This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Greenland Mines Secures Australian Patent for Klotho Gene Therapy Platform Targeting ALS.